Leht 1 alates 59 tulemused
1. INTRODUCTION
The present invention relates to the use of lipase inhibitors for the treatment of pancreatitis and/or organ failure.
2. BACKGROUND OF THE INVENTION
Obesity is a well documented risk factor for worse outcomes in acute pancreatitis (Martinez, et al., Pancreatology 2006, 6:206-209;
PRIORITY CLAIM
This application claims priority to U.S. Provisional Application No. 61/476,119, filed Apr. 15, 2011, the contents of which is hereby incorporated by reference in its entirety herein.
1. INTRODUCTION
The present invention relates to the use of lipase inhibitors for the treatment of
FIELD
The present invention relates to compositions and formulations comprising therapeutically or prophylactically active compounds or pharmaceutically acceptable salts thereof, methods for modulating the activity of Lyn kinase and methods for treating disorders associated with Lyn kinase. In
FIELD
The present invention relates to compositions and formulations comprising therapeutically or prophylactically active compounds or pharmaceutically acceptable salts thereof, methods for modulating the activity of Lyn kinase and methods for treating disorders associated with Lyn kinase. In
1. FIELD OF THE INVENTION
The present invention relates to compositions and formulations comprising therapeutically or prophylactically active compounds or pharmaceutically acceptable salts thereof, methods for modulating the activity of Lyn kinase and methods for treating disorders associated with
FIELD
The present invention relates to compositions and formulations comprising therapeutically or prophylactically active compounds or pharmaceutically acceptable salts thereof, methods for modulating the activity of Lyn kinase and methods for treating disorders associated with Lyn kinase. In
1. FIELD OF THE INVENTION
The present invention relates to compositions and formulations comprising therapeutically or prophylactically active compounds or pharmaceutically acceptable salts thereof, methods for modulating the activity of Lyn kinase and methods for treating disorders associated with
1. FIELD OF THE INVENTION
The present invention relates to compositions and formulations comprising therapeutically or prophylactically active compounds or pharmaceutically acceptable salts thereof, methods for modulating the activity of Lyn kinase and methods for treating disorders associated with
TECHNICAL FIELD
The present invention relates to a nitrogen-containing bicyclic compound or a pharmacologically acceptable salt thereof and a pharmaceutical composition comprising it as active ingredient.
More specifically, the present invention relates to (1) a compound of formula (I)
##STR00002##
The present invention is concerned with novel aryl piperidine or piperazine compounds substituted with certain 5-membered heterocycles having apoB secretion/MTP inhibiting activity and concomitant lipid lowering activity. The invention further relates to methods for preparing such compounds,
The present invention is concerned with novel aryl piperidine or piperazine compounds substituted with certain 5-membered heterocycles having apoB secretion/MTP inhibiting activity and concomitant lipid lowering activity. The invention further relates to methods for preparing such compounds,
TECHNICAL FIELD
The present invention relates to a new compound which is useful as a medicament or a cosmetic, to a process for producing the same and to a pharmaceutical composition comprising the same.
BACKGROUND ART
The melanocortin (MC) is a group of peptide hormones that are derived from
TECHNICAL FIELD
The embodiments disclosed in this specification relates to herbal formulation effective in the treatment, management and prevention of metabolic disorders, and more particularly in the treatment of dyslipidemia. It also relates to the process of preparation of such
FIELD OF THE INVENTION
The present invention relates to novel conjugates of GDF15 which have improved half-life and duration of action, method of making them and using them. The invention further relates to novel fatty acids and their use in extending the half-life of biomolecules via
TECHNICAL FIELD
This invention relates to a novel 3-piperidyl-4-oxoquinazoline derivative. More specifically, it relates to a pharmaceutical composition comprising a 3-piperidyl-4-oxoquinazoline derivative having microsomal triglyceride transfer protein (MTP)-inhibitory activity or its